bufalin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, CC; Liu, XD; Song, CY; Tian, X | 1 |
| Che, X; Li, C; Liu, Y; Ma, Y; Qu, X; Teng, Y; Wang, Q; Wang, Y; Zheng, H; Zhu, Z | 1 |
| Chen, H; Chen, J; Li, F; Liu, X; Lonard, DM; O'Malley, BW; Qin, L; Song, X; Wang, J; Wang, X; Xu, J; Zhang, C; Zhao, M | 1 |
3 other study(ies) available for bufalin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway.
Topics: Antioxidants; Apoptosis; Bufanolides; Caspase 3; Cell Line; Cell Line, Tumor; Cysteine; Docetaxel; Doxorubicin; Fluorescein-5-isothiocyanate; Humans; Necroptosis; Propidium; Reactive Oxygen Species; Receptors, Tumor Necrosis Factor; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2022 |
miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bufanolides; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Humans; MicroRNAs; Triple Negative Breast Neoplasms | 2016 |
Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.
Topics: Animals; Bufanolides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Mice; Mice, Inbred ICR; Mice, SCID; Nuclear Receptor Coactivator 3; Prodrugs; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2015 |